This website isn’t supported by Internet Explorer. We recommend that you use a different browser (e.g. Edge, Chrome, Firefox, Safari, or similar) for the best experience of our content.

For healthcare professionals only

You are viewing the Novo Nordisk Virtual platform, provided to non-US health care professionals from around the world. By accessing this site and materials you accept this legal notice and expressly confirm your status as a healthcare professional.


This site is not country-specific and therefore may contain information which is not applicable to your country. Therefore, before prescribing any product, always refer to local materials such as the prescribing information and/or the Summary of Product Characteristics.


This site is not intended to provide medical advice and/or treatment guidance. Novo Nordisk accepts no liability for the accuracy, completeness or use of the information, and disclaims any liability to update the information contained on this site.

I hereby declare I am a non-US health care professional and that I have read and agreed to the terms mentioned above.

When it comes to comorbid cardiovascular disease and diabetes, the numbers show how important it is that these conditions are identified and managed appropriately. Key to effective management is enabling patients to understand the risks and empowering them to take positive action to reduce them. But engaging in this kind of discussion can be time consuming – the resources on Diabetes, What’s Next can help.



Global guidelines recommend people with type 2 diabetes who are also at high risk of cardiovascular disease should be prescribed a glucose-lowering diabetes medication with proven cardiovascular benefit (e.g., SGLT2 inhibitors and GLP-1 receptor agonists).5-10 However, only a small proportion of eligible patients actually receive these life-saving medications.1


What’s more, people with type 2 diabetes may be unaware of their increased risk of cardiovascular disease and this may mean they are less likely to make choices that can reduce their risk. So it’s incredibly important for people with diabetes to complement discussions with their healthcare professional with high quality, accurate information about cardiovascular disease that can empower them to make positive changes.


While the rise of fake information on the internet and social media can make it hard for people to know where to look, the Diabetes, What’s Next website offers a reliable source of information for patients to learn more about cardiovascular disease and how to reduce their risk.

“I sometimes think that if only I had known then what I know now about diabetes complications, then maybe my heart attack could have been prevented.”

Is type 2 diabetes putting you at risk of heart disease?

Is type 2 diabetes putting you at risk of heart disease?


A blog outlining how managing the symptoms of diabetes effectively can reduce risk of heart disease.


What is atherosclerotic cardiovascular disease (ASCVD)

What is atherosclerotic cardiovascular disease (ASCVD)?


An article outlining what Atherosclerosis is and why it is particularly common in people living with type 2 diabetes.


If only I had known then what I know

If only I had known then what I know now


An interview with Marta, who is living with type 2 diabetes. Her heart attack at age 48 completely transformed the way she was looking at her life with diabetes and high blood pressure. 

The time you have with your patients is often short and there can be a lot to get through. But you can rely on Diabetes, What’s Next to answer questions from your patients that go beyond the medical, enabling you to focus on treatment. 

Direct your patients to Diabetes, What’s Next to take advantage of all its benefits: 


  • Valuable, accurate information in an easy-to-digest format
  • A community of people living with diabetes
  • Empower patients to educate themselves and take control of their condition
  • Equip patients with the knowledge they need to change their lifestyle


Mosenzon O, Alguwaihes A, Arenas Leon J, et al. CAPTURE: a multinational, cross‑sectional study of cardiovascular disease prevalence in adults with type 2 diabetes across 13 countries. Cardiovascular Diabetology 2021; 20: 154.


Barquera S, Pedroza-Tobías A, Medina C, et al. Global overview of the epidemiology of atherosclerotic cardiovascular disease. Archives of Medical Research 2015; 46: 328–338.


Almdal T, Scharling H, Skov Jensen J, et al. The Independent Effect of Type 2 Diabetes Mellitus on Ischemic Heart Disease, Stroke, and Death. Archives of Internal Medicine 2004; 164: 1422–1426.


Fox CS, Coady S, Sorlie PD, et al. Trends in Cardiovascular Complications of Diabetes. Journal of the American Medical Association 2004; 292: 2495–2499.


Das SR, Everett BM, Birtcher KK, et al. 2020 expert consensus decision pathway on novel therapies for cardiovascular risk reduction in patients with type 2 diabetes: a report of the American College of Cardiology Solution Set Oversight Committee. Journal of the American College of Cardiology 2020; 76: 1117–1145.


American Diabetes Association. 10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes-2020. Diabetes Care 2020; 43.


Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Journal of the American College of Cardiology 2019; 74: e177–e232.


Buse JB, Wexler DJ, Tsapas A, et al. 2019 update to: Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2020; 63: 221–228.


Cosentino F, Grant PJ, Aboyans V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: The Task Force for diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD). European Heart Journal 2020; 41: 255–323.


Niessner A, Tamargo J, Koller L, et al. Non-insulin antidiabetic pharmacotherapy in patients with established cardiovascular disease: a position paper of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy. European Heart Journal 2018; 39: 2274–2281.